
Sign up to save your podcasts
Or


For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/NAX865. CME/MOC/AAPA credit will be available until December 16, 2024.
Shattering the Barriers to Glioblastoma Care: Revolutionary Advances With Innovative Technologies and Modern Systemic Approaches
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and American Brain Tumor Association. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported by educational grants from Blue Earth Diagnostics and Novocure, Inc.
Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Steven Brem, MD, has no financial interests/relationships or affiliations in relation to this activity.
Faculty/Planner
Manmeet S. Ahluwalia, MD, MBA, FASCO, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AnHeart Therapeutics; Apollomics, Inc.; Autem Therapeutics; Bayer Corporation; Bugworks; Cairn Therapeutics; Caris Life Sciences; Celularity, Inc.; GSK; GT Medical Technologies; Insightec; Janssen Pharmaceuticals, Inc.; Kiyatec Inc.; Modifi Bio; NH TherAguix; Novocure, Inc.; Nuvation Bio, Inc.; Prelude Therapeutics; Pyramid Biosciences; Sumitomo Dainippon Pharma Oncology; The Menarini Group; Tocagen Inc.; Varian Medical Systems, Inc.; ViewRay Technologies, Inc.; Voyager Therapeutics, Inc.; and Xoft, a subsidiary of iCAD, Inc.
Grant/Research Support from Seagen Inc.
Stock Shareholder in CytoDyn Inc.; MedInnovate Advisors LLC; and MimiVax, LLC.
Faculty/Planner
Michelle Kim, MD, has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from Blue Earth Diagnostics.
Patient/Planner
JB Bird has no financial interests/relationships or affiliations in relation to this activity.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
By PVI, PeerView Institute for Medical Education4.1
2525 ratings
For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/NAX865. CME/MOC/AAPA credit will be available until December 16, 2024.
Shattering the Barriers to Glioblastoma Care: Revolutionary Advances With Innovative Technologies and Modern Systemic Approaches
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and American Brain Tumor Association. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported by educational grants from Blue Earth Diagnostics and Novocure, Inc.
Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Steven Brem, MD, has no financial interests/relationships or affiliations in relation to this activity.
Faculty/Planner
Manmeet S. Ahluwalia, MD, MBA, FASCO, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AnHeart Therapeutics; Apollomics, Inc.; Autem Therapeutics; Bayer Corporation; Bugworks; Cairn Therapeutics; Caris Life Sciences; Celularity, Inc.; GSK; GT Medical Technologies; Insightec; Janssen Pharmaceuticals, Inc.; Kiyatec Inc.; Modifi Bio; NH TherAguix; Novocure, Inc.; Nuvation Bio, Inc.; Prelude Therapeutics; Pyramid Biosciences; Sumitomo Dainippon Pharma Oncology; The Menarini Group; Tocagen Inc.; Varian Medical Systems, Inc.; ViewRay Technologies, Inc.; Voyager Therapeutics, Inc.; and Xoft, a subsidiary of iCAD, Inc.
Grant/Research Support from Seagen Inc.
Stock Shareholder in CytoDyn Inc.; MedInnovate Advisors LLC; and MimiVax, LLC.
Faculty/Planner
Michelle Kim, MD, has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from Blue Earth Diagnostics.
Patient/Planner
JB Bird has no financial interests/relationships or affiliations in relation to this activity.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

43,587 Listeners

137 Listeners

320 Listeners

699 Listeners

497 Listeners

29 Listeners

11 Listeners

1,384 Listeners

5 Listeners

11 Listeners

3 Listeners

2 Listeners

5 Listeners

2 Listeners

3 Listeners

5 Listeners

5 Listeners

2 Listeners

0 Listeners

9 Listeners

2 Listeners

11 Listeners

2 Listeners

881 Listeners

4 Listeners

3 Listeners

5 Listeners

3,350 Listeners

1,146 Listeners

193 Listeners

93 Listeners

513 Listeners

369 Listeners

425 Listeners